23,036,271
Vote Records
25,695
Companies
11,771
Funds
3,902
Managers

Home › Companies › SPRINGWORKS THERAPEUTICS INC. › 2023-2024

SPRINGWORKS THERAPEUTICS INC. 2023-2024 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and SPRINGWORKS THERAPEUTICS INC.’s Form 8-K, filed May 17, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 3Ballot items
  • 215Asset managers, any item
  • 1,034Fund votes
  • May 16, 2024Meeting date

Results at a glance

Meeting of May 16, 2024: 3 items on SPRINGWORKS THERAPEUTICS INC.’s Form 8-K, filed May 17, 2024: 2 approved · 1 passed (calculated).

Dissent

Significant dissent: 1 director (23.9% against); 1 say-on-pay vote (58.0% support).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025

Explore SPRINGWORKS THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by SPRINGWORKS THERAPEUTICS INC.

These tallies are SPRINGWORKS THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 17, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

SPRINGWORKS THERAPEUTICS INC. — official shareholder meeting results, meeting held May 16, 2024
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Freda Lewis-Hall 50,328,375---- 15,800,834-- 76%Passed (calculated)—
2. Ratification of Appointment of Independent Registered Public Accounting Firm 69,485,3225,70910,294 ---- 99.9%Approved—
3. Non-Binding Advisory Vote on Executive Compensation 38,332,46327,761,536-- ---- 58%Approved—

Source: SPRINGWORKS THERAPEUTICS INC., Form 8-K, filed with the SEC on May 17, 2024 — read the filing on EDGAR.

How asset managers voted at the SPRINGWORKS THERAPEUTICS INC. 2023-2024 meeting

215 asset managers disclosed a vote on at least one SPRINGWORKS THERAPEUTICS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Freda Lewis-Hall

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 2 wordings of this item as funds reported it.

76% Majority: yes · of votes cast

FOR 76%WITHHELD
FOR: 50,328,375WITHHELD: 15,800,834
Details: description as filed, official tally, votes by 68 asset managers

Description as filed by funds: ELECTION OF CLASS II DIRECTOR: FREDA LEWIS-HALL

SPRINGWORKS THERAPEUTICS INC.’s own tally for this item (“Elect Director: Freda Lewis-Hall”): 50,328,375 for, 15,800,834 withheld, per its Form 8-K filed May 17, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 76% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 68 asset managers below reported 24,531,849 for, 3,840,371 withheld.

FOR
FOR: 24,531,849WITHHOLD: 3,840,371
Largest asset managers voting on “ELECTION OF CLASS II DIRECTOR: FREDA LEWIS-HALL” at SPRINGWORKS THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity8,017,7800 01,400For
Vanguard7,000,5440 00For
T. Rowe Price3,187,9780 00For
BlackRock2,048,1930 00For
Lord Abbett1,985,2560 00For
State Street8200 0822,806Withhold
Charles Schwab517,6890 00For
Dimensional00 0458,491Withhold
Voya00 0452,700Withhold
Columbia Threadneedle434,8720 00For
MFS00 0398,622Withhold
Invesco00 0373,777Withhold
Victory Capital00 0361,448Withhold
MERIDIAN FUND INC328,8320 00For
Equitable123,6240 068,130Mixed
TIAA174,5790 00For
Bridge Builder Trust12,5010 0123,725Mixed
QUANTITATIVE MASTER SERIES LLC118,4760 00For
John Hancock53,5310 045,639Mixed
New York Life83,3720 012,447Mixed
Russell Investments88,2400 00For
AIG/SunAmerica00 085,962Withhold
Direxion Shares ETF Trust00 081,412Withhold
MoA Funds Corp00 081,047Withhold
Jackson National00 072,517Withhold

Showing the 25 largest of 68 asset managers. All 68 are in the interactive database (link above).

Non-Binding Advisory Vote on Executive Compensation

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 6 wordings of this item as funds reported it.

58% Approved · of votes cast

FOR 58%AGAINST
FOR: 38,332,463AGAINST: 27,761,536
Details: description as filed, official tally, votes by 214 asset managers

Description as filed by funds: Non-binding advisory vote on executive compensation

SPRINGWORKS THERAPEUTICS INC.’s own tally for this item (“3. Non-Binding Advisory Vote on Executive Compensation”): 38,332,463 for, 27,761,536 against — passed, per its Form 8-K filed May 17, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3 - Non-Binding Advisory Vote on Executive Compensation The stockholders approved, on a non-binding advisory basis, the compensation of the Company's named executive officers, as disclosed in the Company's proxy statement for the annual meeting of stockholders.”
Support: 58% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 68 asset managers voting on “Non-binding advisory vote on executive compensation” at SPRINGWORKS THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity6,424,0661,595,114 00Mixed
Vanguard6,342,281658,263 00Mixed
T. Rowe Price03,187,978 00Against
BlackRock02,048,193 00Against
Lord Abbett1,985,2560 00For
State Street822,5121,114 00For
Charles Schwab0517,689 00Against
Dimensional0458,491 00Against
Voya0452,700 00Against
Columbia Threadneedle0434,872 00Against
MFS0398,622 00Against
Invesco0373,777 00Against
Victory Capital0361,448 00Against
MERIDIAN FUND INC0328,832 00Against
Equitable0191,754 00Against
TIAA0174,579 00Against
Bridge Builder Trust0136,226 00Against
QUANTITATIVE MASTER SERIES LLC0118,476 00Against
John Hancock099,170 00Against
New York Life095,819 00Against
Russell Investments088,240 00Against
AIG/SunAmerica085,962 00Against
Direxion Shares ETF Trust081,412 00Against
MoA Funds Corp081,047 00Against
Jackson National072,517 00Against

Fund voting reports, all 68 managers: 15,745,294 for, 12,618,602 against, 8,324 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 175 asset managers voting on “Non-binding advisory vote on executive compensation” at SPRINGWORKS THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity11,067,8610 00For
New York Life09,000,000 00Against
T. Rowe Price03,969,881 00Against
LORD, ABBETT & CO. LLC2,159,8580 00For
State Street2,074,14817,512 00For
MARSHALL WACE, LLP01,975,620 00Against
ORBIMED ADVISORS LLC1,707,3310 00For
ArrowMark Colorado Holdings LLC01,681,318 00Against
BlackRock27,0251,574,753 00Against
BNP Paribas Asset Management Holding S.A.01,509,922 00Against
Deep Track Capital, LP1,501,7360 00For
Point7201,501,114 00Against
MAVERICK CAPITAL LTD1,462,9310 00For
GEODE CAPITAL MANAGEMENT, LLC01,445,000 00Against
PICTET ASSET MANAGEMENT SA01,368,474 00Against
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)1,283,1760 00For
Woodline Partners LP863,8680 00For
Fiera Capital Corp0824,202 00Against
Victory Capital0624,078 00Against
Finepoint Capital LP0592,528 00Against
Voya0534,095 00Against
Charles Schwab0517,689 00Against
Northern Trust460,0593,688 00For
Invesco0443,648 00Against
MASSACHUSETTS FINANCIAL SERVICES CO /MA/0434,556 00Against

Institutional-manager reports, all 175 managers: 23,861,548 for, 33,340,253 against, 1,279 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of Appointment of Independent Registered Public Accounting Firm

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 3 wordings of this item as funds reported it.

99.9% Approved · of votes cast

FOR 99.9%
FOR: 69,485,322AGAINST: 5,709
Details: description as filed, official tally, votes by 68 asset managers

Description as filed by funds: Ratification of the appointment of Ernst & Young LLP as SpringWorks Therapeutics' independent registered public accounting firm for the fiscal year ending December 31, 2024

SPRINGWORKS THERAPEUTICS INC.’s own tally for this item (“2. Ratification of Appointment of Independent Registered Public Accounting Firm”): 69,485,322 for, 5,709 against — passed, per its Form 8-K filed May 17, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 2 - Ratification of Appointment of Independent Registered Public Accounting Firm The stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 68 asset managers below reported 28,363,729 for, 167 against, 8,324 abstained.

FOR
FOR: 28,363,729AGAINST: 167ABSTAIN: 8,324
Largest asset managers voting on “Ratification of the appointment of Ernst & Young LLP as SpringWorks Therapeutics' independent registered publi” at SPRINGWORKS THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity8,019,1800 00For
Vanguard7,000,5440 00For
T. Rowe Price3,187,9780 00For
BlackRock2,048,1930 00For
Lord Abbett1,985,2560 00For
State Street823,6260 00For
Charles Schwab517,6890 00For
Dimensional458,4910 00For
Voya452,7000 00For
Columbia Threadneedle434,8720 00For
MFS398,6220 00For
Invesco373,7770 00For
Victory Capital361,4480 00For
MERIDIAN FUND INC328,8320 00For
Equitable191,7540 00For
TIAA174,5790 00For
Bridge Builder Trust136,2260 00For
QUANTITATIVE MASTER SERIES LLC118,4760 00For
John Hancock99,1700 00For
New York Life95,8190 00For
Russell Investments88,2400 00For
AIG/SunAmerica85,9620 00For
Direxion Shares ETF Trust81,4120 00For
MoA Funds Corp81,0470 00For
Jackson National72,5170 00For

Showing the 25 largest of 68 asset managers. All 68 are in the interactive database (link above).

Largest SPRINGWORKS THERAPEUTICS INC. shareholders voting in 2023-2024

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported.

Fund voting reports: top SPRINGWORKS THERAPEUTICS INC. shareholders by shares voted on “Non-binding advisory vote on executive compensation”, 2023-2024
#Asset manager Shares voted
1Fidelity 8,019,180
2Vanguard 7,000,544
3T. Rowe Price 3,187,978
4BlackRock 2,048,193
5Lord Abbett 1,985,256
6State Street 823,626
7Charles Schwab 517,689
8Dimensional 458,491
9Voya 452,700
10Columbia Threadneedle 434,872
Institutional-manager reports: top SPRINGWORKS THERAPEUTICS INC. shareholders by shares voted on “Non-binding advisory vote on executive compensation”, 2023-2024
#Asset manager Shares voted
1Fidelity 11,067,861
2New York Life 9,000,000
3T. Rowe Price 3,969,881
4LORD, ABBETT & CO. LLC 2,159,858
5State Street 2,091,660
6MARSHALL WACE, LLP 1,975,620
7ORBIMED ADVISORS LLC 1,707,331
8ArrowMark Colorado Holdings LLC 1,681,318
9BlackRock 1,601,778
10BNP Paribas Asset Management Holding S.A. 1,509,922

Shown as share counts, not percentages: no shares-outstanding figure has been matched to SPRINGWORKS THERAPEUTICS INC. for the 2023-2024 season, so there is no denominator to divide by.

About this meeting

At SPRINGWORKS THERAPEUTICS INC.'s shareholder meeting held May 16, 2024, in the 2023-2024 proxy season, 215 asset managers reported votes on at least one of its 3 ballot items in their SEC Form N-PX filings, covering 1,034 separate fund positions. On the most widely held item on that ballot — Non-binding advisory vote on executive compensation — SPRINGWORKS THERAPEUTICS INC.'s filing reports the proposal as approved, with 58% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: SPRINGWORKS THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 17, 2024.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

SPRINGWORKS THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025.

Cite this page

Proxy Votes Now, “SPRINGWORKS THERAPEUTICS INC. 2024 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/springworks-therapeutics-inc/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.